Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

238 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.
Hardy NM, Fellowes V, Rose JJ, Odom J, Pittaluga S, Steinberg SM, Blacklock-Schuver B, Avila DN, Memon S, Kurlander RJ, Khuu HM, Stetler-Stevenson M, Mena E, Dwyer AJ, Levine BL, June CH, Reshef R, Vonderheide RH, Gress RE, Fowler DH, Hakim FT, Bishop MR. Hardy NM, et al. Among authors: bishop mr. Blood. 2012 Mar 22;119(12):2956-9. doi: 10.1182/blood-2011-09-378398. Epub 2012 Jan 30. Blood. 2012. PMID: 22289893 Free PMC article. Clinical Trial.
Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
Bishop MR, Hou JW, Wilson WH, Steinberg SM, Odom J, Castro K, Kasten-Sportes C, Gea-Banacloche J, Marchigiani D, Gress R, Fowler DH. Bishop MR, et al. Biol Blood Marrow Transplant. 2003 Mar;9(3):162-9. doi: 10.1053/bbmt.2003.50008. Biol Blood Marrow Transplant. 2003. PMID: 12652466 Free article. Clinical Trial.
Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation.
Fowler DH, Odom J, Steinberg SM, Chow CK, Foley J, Kogan Y, Hou J, Gea-Banacloche J, Sportes C, Pavletic S, Leitman S, Read EJ, Carter C, Kolstad A, Fox R, Beatty GL, Vonderheide RH, Levine BL, June CH, Gress RE, Bishop MR. Fowler DH, et al. Among authors: bishop mr. Biol Blood Marrow Transplant. 2006 Nov;12(11):1150-60. doi: 10.1016/j.bbmt.2006.06.015. Biol Blood Marrow Transplant. 2006. PMID: 17085308 Free article. Clinical Trial.
Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation.
Hardy NM, Hakim F, Steinberg SM, Krumlauf M, Cvitkovic R, Babb R, Odom J, Fowler DH, Gress RE, Bishop MR. Hardy NM, et al. Among authors: bishop mr. Biol Blood Marrow Transplant. 2007 Sep;13(9):1022-30. doi: 10.1016/j.bbmt.2007.05.008. Epub 2007 Jul 16. Biol Blood Marrow Transplant. 2007. PMID: 17697964 Free PMC article.
Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels.
Boyiadzis M, Memon S, Carson J, Allen K, Szczepanski MJ, Vance BA, Dean R, Bishop MR, Gress RE, Hakim FT. Boyiadzis M, et al. Among authors: bishop mr. Biol Blood Marrow Transplant. 2008 Mar;14(3):290-300. doi: 10.1016/j.bbmt.2007.12.490. Biol Blood Marrow Transplant. 2008. PMID: 18275895 Free article.
Strategies to improve long-term outcome in stage IIIB inflammatory breast cancer: multimodality treatment including dose-intensive induction and high-dose chemotherapy.
Sportès C, Steinberg SM, Liewehr DJ, Gea-Banacloche J, Danforth DN, Avila DN, Bryant KE, Krumlauf MC, Fowler DH, Pavletic S, Hardy NM, Bishop MR, Gress RE. Sportès C, et al. Among authors: bishop mr. Biol Blood Marrow Transplant. 2009 Aug;15(8):963-70. doi: 10.1016/j.bbmt.2009.04.018. Biol Blood Marrow Transplant. 2009. PMID: 19589486 Free PMC article. Clinical Trial.
238 results